JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 27, 2006; DOI: 10.1124/jpet.106.103465

0022-3565/06/3183-933-938$20.00
JPET 318:933-938, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.103465v1
318/3/933    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Medina, C.
Right arrow Articles by Radomski, M. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medina, C.
Right arrow Articles by Radomski, M. W.

PERSPECTIVES IN PHARMACOLOGY

Role of Matrix Metalloproteinases in Intestinal Inflammation

Carlos Medina, and Marek W. Radomski

School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin, Ireland and Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, Texas

Matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of MMPs (TIMPs), are produced in the gastrointestinal tract by several structural cells. The balance between MMPs and TIMPs is essential for many physiological processes in the gut. However, imbalance between MMPs and TIMPs plays an important role in the pathophysiology of diverse intestinal inflammatory conditions. We reviewed the role of the MMP/TIMP system in the pathogenesis of intestinal inflammatory diseases and pharmacologic perspectives for the use of compounds that restore the MMP/TIMP balance.

Received March 1, 2006; accepted April 24, 2006.

Address correspondence to: Dr. Marek W. Radomski, Chair of Pharmacology, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland. E-mail: radomskm{at}tcd.ie




This article has been cited by other articles:


Home page
 GutHome page
L Menchen, I Marin-Jimenez, E G Arias-Salgado, T Fontela, P Hernandez-Sampelayo, M C G. Rodriguez, and N V Butta
Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand
Gut, July 1, 2009; 58(7): 920 - 928.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. Sokal, M. Zembala, A. Radomski, A. Kocher, J. Pacholewicz, J. Los, E. Jedrzejczyk, M. Zembala, and M. Radomski
A differential release of matrix metalloproteinases 9 and 2 during coronary artery bypass grafting and off-pump coronary artery bypass surgery.
J. Thorac. Cardiovasc. Surg., May 1, 2009; 137(5): 1218 - 1224.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. Ishida, S. Takai, M. Murano, T. Nishikawa, T. Inoue, N. Murano, N. Inoue, D. Jin, E. Umegaki, K. Higuchi, et al.
Role of Chymase-Dependent Matrix Metalloproteinase-9 Activation in Mice with Dextran Sodium Sulfate-Induced Colitis
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 422 - 426.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.